BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jan 10, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Bavituximab: Phase II started

Peregrine began an open-label U.S. Phase II trial to compare 1,000 mg/m 2 Gemzar gemcitabine given on days 1, 8, and 15...

Read the full 100 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >